Form 4: Glaukos Director Foley Granted Restricted Stock Units

Glaukos Corporation Director Mark J Foley was granted 1,168 restricted stock units, vesting in one year, as part of the company's director compensation policy.

Summary

• Mark J Foley, a Director of Glaukos Corporation (GKOS), was granted 1,168 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this grant was January 2, 2026.
• These RSUs were granted at a price of $0 per unit, indicating they are part of a compensation package.
• The units will vest in full on the one-year anniversary of the grant date, which is January 2, 2027.
• Upon vesting, the RSUs are payable in an equivalent number of shares of Glaukos' common stock.
• Following this transaction, Mark J Foley beneficially owns 58,389 shares of common stock directly.
• The total beneficial ownership includes 3,276 restricted stock units that have not yet vested or been delivered.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of restricted stock units to a director is a routine compensation event that aligns management interests with shareholders. It does not indicate any immediate operational or financial performance issues, nor does it suggest extraordinary positive developments beyond standard governance practices.

Positives

• The grant of restricted stock units to Director Mark J Foley aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• This transaction is part of a standard Director Compensation Policy, indicating a structured approach to executive and director incentives.

Future Outlook

The 1,168 restricted stock units granted to Director Mark J Foley are scheduled to vest in full on January 2, 2027, at which point they will be payable in an equivalent number of shares of Glaukos' common stock.

Industry Context

The grant of restricted stock units to a director is a common practice in the medical device and broader corporate sectors. It serves as a form of long-term incentive compensation, aiming to align the interests of the director with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) as part of director compensation is a widely adopted practice across various industries, including medical technology, and is consistent with corporate governance best practices aimed at aligning director incentives with shareholder interests.
• The one-year vesting period for these RSUs is a common structure for annual director equity grants, similar to practices observed at comparable medical device companies such as Alcon (ALC) or Bausch + Lomb (BLCO), which often use equity awards to compensate non-employee directors.

Related Party Transactions

• The grant of 1,168 restricted stock units to Director Mark J Foley constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors, executed under the Issuer's Director Compensation Policy.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can positively impact shareholders by aligning the director's financial interests with the long-term performance of the company's stock.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The 1,168 restricted stock units are expected to vest on January 2, 2027, and subsequently be delivered as common stock.

Key Dates

Keywords

Glaukos, GKOS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Mark J Foley